AUSTIN, Texas, Jan. 14, 2025 /PRNewswire/ — DiFusion Applied sciences, an trade chief in superior biomaterials for surgical implants, introduced in the present day the issuance of a brand new US Patent 12,178,936 B2 “Medical Implants and Strategies of Manufacture.”
The brand new patent is encompasses 4 strategies to fabricate ZFUZE® a proprietary therapeutic, anti-inflammatory, osseoconductive, load bearing biomaterial for orthopedic implants. ZFUZE is the primary FDA-cleared superior biomaterial for spinal implants that’s confirmed to create a extremely favorable mobile and immunologic response post-surgery. A current spectacular discovering, is a 75 affected person retrospective examine, whereby ZFUZE posted a dominant 93.4% lumbar spinal fusion price at 6 months whereas comparable aggressive research display common lumbar fusion charges of 68% at 12 months.
“This new patent firmly protects our ZFUZE FDA Grasp File for an additional 17 years. ZFUZE is the one FDA cleared immuno-modulating biomaterial presently out there to sufferers’ surgeons and hospitals,” DiFusion Founder and CEO Derrick Johns. “Constructing a FDA Grasp File is an extended, arduous and costly course of that bigger orthopedic firms usually are not scientifically outfitted to execute,” added Johns.
About DiFusion Applied sciences:
DiFusion Applied sciences, Inc. is an trade chief in superior biomaterials for surgical implants. DiFusion is revolutionizing the sector of implant know-how by creating modern options that scale back the overseas physique response from the affected person’s immune system, thereby selling early therapeutic, decreasing issues, and bettering affected person outcomes. The corporate’s proprietary manufacturing course of produces implants that lower continual irritation presently related to mainstream biomaterials.
Contact: ceo@difusiontech.com (512) 574-1755 www.difusiontech.com
SOURCE DiFusion Inc.
Discussion about this post